Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Alaa Muslimani

Medical Oncology Rock Hill, SC Medical Doctor

NPI 1881887826 CMS profile 176775

1656 Riverchase Blvd, Ste 1400, Rock Hill, SC 29732

Open in the dashboard

General payments

$8,943

8 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Alaa Muslimani of Rock Hill, SC is reported in the CMS Open Payments database as having received $8,943 across 8 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $4,131 4
2022 General $1,600 1
2021 General $1,712 2
2019 General $1,500 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alaa Muslimani
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Alaa Muslimani were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Alaa Muslimani Medical Oncology median Middle half National median
2019 $1,500 $968 $140–$6,658 $163
2020 $0 $747 $102–$5,891 $114
2021 $1,712 $430 $50–$4,098 $132
2022 $1,600 $812 $127–$4,907 $149
2023 $4,131 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Kite Pharma, Inc. $4,910 3 payments
  2. AstraZeneca Pharmaceuticals LP $2,508 2 payments
  3. Seattle Genetics, Inc. $1,500 1 payment
  4. Pfizer Inc. $13 1 payment
  5. Gilead Sciences, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $7,408 4 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 1 payment
  3. Education $25 2 payments
  4. Travel and Lodging $10 1 payment
Products named General payments · program years 2019–2023
  1. Tecartus $4,910 3 payments
  2. IMFINZI $2,508 2 payments
  3. IBRANCE $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,255

Median for Medical Oncology: 414

Drug cost

$4,461,843

Median for Medical Oncology: $849,427

Branded share of claims

26.7%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imbruvica Ibrutinib Brand 38 $598,334
Jakafi Ruxolitinib Phosphate Brand 36 $515,846
Lenalidomide Generic 34 $476,141
Calquence Acalabrutinib Maleate Brand 26 $387,629
Revlimid Lenalidomide Brand 17 $348,601
Lenvima Lenvatinib Mesylate Brand 15 $341,214
Onureg Azacitidine Brand 13 $337,650
Tasigna Nilotinib Hcl Brand 13 $249,207
Verzenio Abemaciclib Brand 13 $196,013
Promacta Eltrombopag Olamine Brand 14 $189,344

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 167 billing codes

Paid by Medicare

$4,611,935

Of which drugs: $4,301,407

Medicare patients

730

Average age 75

Services billed

220,056

399 women, 331 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 45%
Arthritis 42%
Diabetes 35%
Ischemic heart disease 34%
Chronic kidney disease 28%
Depression 24%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 26 24,000 $1,069,440
Injection, nivolumab, 1 mg J9299 Office 11 12,320 $302,727
Injection, denosumab, 1 mg J0897 Office 28 4,380 $90,832
Injection, paclitaxel protein-bound particles, 1 mg J9264 Office 12 5,200 $49,877
Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg Q5111 Office 19 480 $49,715
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg Q5118 Office 11 2,500 $41,310
Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 Office 15 5,300 $11,316
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 Office 46 30,090 $8,016
Injection, leucovorin calcium, per 50 mg J0640 Office 15 1,451 $5,204
Injection, fluorouracil, 500 mg J9190 Office 16 877 $2,056

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

8 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record